A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF21) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 LIVER FIBROSIS.
Research Grant
Administered By
Radiology, Abdominal Imaging
Awarded By
Bristol-Myers Squibb Company
Start Date
November 5, 2018
End Date
October 31, 2019
Administered By
Radiology, Abdominal Imaging
Awarded By
Bristol-Myers Squibb Company
Start Date
November 5, 2018
End Date
October 31, 2019